发布求助
文献互助 智能选刊 最新文献

Personalized medicine最新文献

筛选
英文 中文
Attitudes toward pharmacogenetics in patients undergoing CYP2C19 testing following percutaneous coronary intervention. 经皮冠状动脉介入治疗后接受CYP2C19检测的患者对药物遗传学的态度
IF 2.3 4区 医学
Personalized medicine Pub Date : 2022-03-01 Epub Date: 2022-01-05 DOI: 10.2217/pme-2021-0064
Grace Lee, Lisa A Varughese, Laura Conway, Carol Stojinski, Sandhya Ashokkumar, Karen Monono, William Matthai, Daniel M Kolansky, Jay Giri, Sony Tuteja
{"title":"Attitudes toward pharmacogenetics in patients undergoing <i>CYP2C19</i> testing following percutaneous coronary intervention.","authors":"Grace Lee,&nbsp;Lisa A Varughese,&nbsp;Laura Conway,&nbsp;Carol Stojinski,&nbsp;Sandhya Ashokkumar,&nbsp;Karen Monono,&nbsp;William Matthai,&nbsp;Daniel M Kolansky,&nbsp;Jay Giri,&nbsp;Sony Tuteja","doi":"10.2217/pme-2021-0064","DOIUrl":"https://doi.org/10.2217/pme-2021-0064","url":null,"abstract":"<p><p><b>Aim:</b> Patient knowledge and attitudes toward pharmacogenetic (PGx) testing may impact adoption of clinical testing. <b>Methods:</b> Questionnaires regarding knowledge, attitudes and ethics of PGx testing were distributed to 504 patients enrolled in the ADAPT study conducted at two urban hospitals in Philadelphia, Pennsylvania, USA. Responses were assessed using multivariable logistic regression. <b>Results:</b> 311 completed the survey (62% response rate). 74% were unaware of PGx testing, but 79% indicated using PGx results to predict medication efficacy was important. In a multivariable model, higher education level (p = 0.031) and greater genetics knowledge (p < 0.001) were associated with more positive attitudes toward PGx testing. <b>Conclusion:</b> Greater patient knowledge of genetics was associated with a more positive attitude toward PGx testing, indicating that educational strategies aimed at increasing genetics knowledge may enhance adoption of PGx testing in the clinic.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":" ","pages":"93-101"},"PeriodicalIF":2.3,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885847/pdf/nihms-1769033.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39874946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Investigating underlying human immunity genes, implicated diseases and their relationship to COVID-19 研究潜在的人类免疫基因、相关疾病及其与新冠肺炎的关系
IF 2.3 4区 医学
Personalized medicine Pub Date : 2022-01-01 DOI: 10.2217/pme-2021-0132
Zeeshan Ahmed, E. G. Renart, Saman Zeeshan
{"title":"Investigating underlying human immunity genes, implicated diseases and their relationship to COVID-19","authors":"Zeeshan Ahmed, E. G. Renart, Saman Zeeshan","doi":"10.2217/pme-2021-0132","DOIUrl":"https://doi.org/10.2217/pme-2021-0132","url":null,"abstract":"Aim: A human immunogenetics variation study was conducted in samples collected from diverse COVID-19 populations. Materials & methods: Whole-genome and whole-exome sequencing (WGS/WES), data processing, analysis and visualization pipeline were applied to identify variants associated with genes of interest. Results: A total of 2886 mutations were found across the entire set of 13 genomes. Functional annotation of the gene variants revealed mutation type and protein change. Many variants were found to be biologically implicated in COVID-19. The involvement of these genes was also found in multiple other diseases. Conclusion: The analysis determined that ACE2, TMPRSS4, TMPRSS2, SLC6A20 and FYCOI had functional implications and TMPRSS4 was the gene most altered in virally infected patients.","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46020576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Interventional cardiologists' attitudes towards pharmacogenetic testing and impact on antiplatelet prescribing decisions. 介入心脏病专家对药物遗传学检测的态度及其对抗血小板处方决策的影响。
IF 2.3 4区 医学
Personalized medicine Pub Date : 2022-01-01 Epub Date: 2021-12-09 DOI: 10.2217/pme-2021-0088
Glenda Hoffecker, Genevieve P Kanter, Yao Xu, William Matthai, Daniel M Kolansky, Jay Giri, Sony Tuteja
{"title":"Interventional cardiologists' attitudes towards pharmacogenetic testing and impact on antiplatelet prescribing decisions.","authors":"Glenda Hoffecker,&nbsp;Genevieve P Kanter,&nbsp;Yao Xu,&nbsp;William Matthai,&nbsp;Daniel M Kolansky,&nbsp;Jay Giri,&nbsp;Sony Tuteja","doi":"10.2217/pme-2021-0088","DOIUrl":"https://doi.org/10.2217/pme-2021-0088","url":null,"abstract":"<p><p><b>Aim:</b> To determine if interventional cardiologists' knowledge and attitudes toward pharmacogenetic (PGx) testing influenced their antiplatelet prescribing decisions in response to <i>CYP2C19</i> results. <b>Materials & methods:</b> Surveys were administered prior to participating in a randomized trial of <i>CYP2C19</i> testing. Associations between baseline knowledge/attitudes and agreement with the genotype-guided antiplatelet recommendations were determined using multivariable logistic regression. <b>Results:</b> 50% believed that PGx testing would be valuable to predict medication toxicity or efficacy. 64% felt well informed about PGx testing and its therapeutic application. However, PGx experience, knowledge, nor attitudes were significantly associated with agreement to genotype-guided antiplatelet recommendations. <b>Conclusion:</b> Cardiologists' knowledge and attitudes were not associated with <i>CYP2C19-</i>guided antiplatelet prescribing, but larger studies should be done to confirm this finding.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"19 1","pages":"41-49"},"PeriodicalIF":2.3,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39794457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Therapeutic drug monitoring guided fluconazole therapy in a patient with cholangitis sepsis. 治疗药物监测指导氟康唑治疗胆管炎脓毒症1例。
IF 2.3 4区 医学
Personalized medicine Pub Date : 2022-01-01 Epub Date: 2021-11-08 DOI: 10.2217/pme-2021-0010
Jana Duricova, Pavla Jadrnickova, Hana Brozmanova, Ivana Kacirova
{"title":"Therapeutic drug monitoring guided fluconazole therapy in a patient with cholangitis sepsis.","authors":"Jana Duricova,&nbsp;Pavla Jadrnickova,&nbsp;Hana Brozmanova,&nbsp;Ivana Kacirova","doi":"10.2217/pme-2021-0010","DOIUrl":"https://doi.org/10.2217/pme-2021-0010","url":null,"abstract":"<p><p><i>Candida</i> and other fungal species play an increasing role in nosocomial infections, including cholangitis and cholangiosepsis. Early diagnosis and prompt treatment are essential in successful patient outcomes. Fluconazole is an antifungal of choice in fluconazole-sensitive <i>Candida</i> infections. Little information is known about the fluconazole biliary excretion. Decreased tissue penetration may be one of the possible causes of treatment failure. Due to favorable pharmacokinetics, therapeutic drug monitoring of this antifungal has not been recommended routinely. In the presented case we report the successful therapeutic drug monitoring-guided fluconazole treatment in a patient with cholangitis and cholangiosepsis caused by fluconazole-sensitive <i>Candida</i> spp.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"19 1","pages":"9-14"},"PeriodicalIF":2.3,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39688304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
The United States 2020 Census data: implications for precision medicine and the research landscape. 美国2020年人口普查数据:对精准医学和研究前景的影响。
IF 2.3 4区 医学
Personalized medicine Pub Date : 2022-01-01 Epub Date: 2021-11-08 DOI: 10.2217/pme-2021-0129
Youssef Roman
{"title":"The United States 2020 Census data: implications for precision medicine and the research landscape.","authors":"Youssef Roman","doi":"10.2217/pme-2021-0129","DOIUrl":"https://doi.org/10.2217/pme-2021-0129","url":null,"abstract":"","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"19 1","pages":"5-8"},"PeriodicalIF":2.3,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39688307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 14
Somatic mitochondrial DNA mutations in different grades of glioma. 不同级别胶质瘤的体细胞线粒体DNA突变。
IF 2.3 4区 医学
Personalized medicine Pub Date : 2022-01-01 Epub Date: 2021-12-07 DOI: 10.2217/pme-2021-0033
Bee Hong Soon, Nadiah Abu, Nor Azian Abdul Murad, Sue-Mian Then, Azizi Abu Bakar, Farizal Fadzil, Jegan Thanabalan, Mohd Saffari Mohd Haspani, Charng Jeng Toh, Ramesh Kumar, Ainul Syahrilfazli Jaafar, Anis Nabillah Mohd Azli, Mohd Syakir Mohd Azahar, Sanmugarajah Paramasvaran, Kamalanathan Palaniandy, Azmi Mohd Tamil, Rahman Jamal
{"title":"Somatic mitochondrial DNA mutations in different grades of glioma.","authors":"Bee Hong Soon,&nbsp;Nadiah Abu,&nbsp;Nor Azian Abdul Murad,&nbsp;Sue-Mian Then,&nbsp;Azizi Abu Bakar,&nbsp;Farizal Fadzil,&nbsp;Jegan Thanabalan,&nbsp;Mohd Saffari Mohd Haspani,&nbsp;Charng Jeng Toh,&nbsp;Ramesh Kumar,&nbsp;Ainul Syahrilfazli Jaafar,&nbsp;Anis Nabillah Mohd Azli,&nbsp;Mohd Syakir Mohd Azahar,&nbsp;Sanmugarajah Paramasvaran,&nbsp;Kamalanathan Palaniandy,&nbsp;Azmi Mohd Tamil,&nbsp;Rahman Jamal","doi":"10.2217/pme-2021-0033","DOIUrl":"https://doi.org/10.2217/pme-2021-0033","url":null,"abstract":"<p><p><b>Aim:</b> Mitochondrial DNA (mtDNA) alterations play an important role in the multistep processes of cancer development. Gliomas are among the most diagnosed brain cancer. The relationship between mtDNA alterations and different grades of gliomas are still elusive. This study aimed to elucidate the profile of somatic mtDNA mutations in different grades of gliomas and correlate it with clinical phenotype. <b>Materials & methods:</b> Forty histopathologically confirmed glioma tissue samples and their matched blood were collected and subjected for mtDNA sequencing. <b>Results & conclusion:</b> About 75% of the gliomas harbored at least one somatic mutation in the mtDNA gene, and 45% of these mutations were pathogenic. Mutations were scattered across the mtDNA genome, and the commonest nonsynonymous mutations were located at complex I and IV of the mitochondrial respiratory chain. These findings may have implication for future research to determine the mitochondrial energetics and its downstream metabolomics on gliomas.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"19 1","pages":"25-39"},"PeriodicalIF":2.3,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39698808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
HER2 in gastric adenocarcinoma: where do we stand today? 胃腺癌中HER2的研究进展如何?
IF 2.3 4区 医学
Personalized medicine Pub Date : 2022-01-01 Epub Date: 2021-12-09 DOI: 10.2217/pme-2021-0004
Khalil El Gharib, Makram Khoury, Hampig Raphael Kourie
{"title":"HER2 in gastric adenocarcinoma: where do we stand today?","authors":"Khalil El Gharib,&nbsp;Makram Khoury,&nbsp;Hampig Raphael Kourie","doi":"10.2217/pme-2021-0004","DOIUrl":"https://doi.org/10.2217/pme-2021-0004","url":null,"abstract":"<p><p><b>Aim:</b><i>HER2</i> is a proto-oncogene expressed in 10-30% of gastric adenocarcinomas and is an ideal target for inhibition in malignancy with high recurrence and dismal survival rates. <b>Materials & methods:</b> A systematic search was conducted via PubMed, Google Scholar and the clinicaltrials.gov database to report the results of ongoing and past studies investigating HER2 inhibitors in gastric cancer. <b>Results:</b> Twenty-five studies were included; ToGA trial is the pivotal trial approving the use of trastuzumab in metastatic gastric cancer, followed by more studies investigating other HER2 inhibitors in this setting, as well as in local and locoregional malignancy. <b>Conclusion:</b> Anti-HER2 molecules are proving efficacy and safety in gastric cancer; the evidence is growing and association with other cancer agents is under investigation.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"19 1","pages":"67-78"},"PeriodicalIF":2.3,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39794455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Prioritizing pharmacogenomics implementation initiates: a survey of healthcare professionals. 优先考虑药物基因组学实施启动:对医疗保健专业人员的调查。
IF 2.3 4区 医学
Personalized medicine Pub Date : 2022-01-01 Epub Date: 2021-12-09 DOI: 10.2217/pme-2021-0061
Teresa T Ho, Maja Gift, Earnest Alexander
{"title":"Prioritizing pharmacogenomics implementation initiates: a survey of healthcare professionals.","authors":"Teresa T Ho,&nbsp;Maja Gift,&nbsp;Earnest Alexander","doi":"10.2217/pme-2021-0061","DOIUrl":"https://doi.org/10.2217/pme-2021-0061","url":null,"abstract":"<p><p><b>Aim:</b> Characterize current perceptions, practices, preferences and barriers to integrating pharmacogenomics into patient care at an institution with an established pharmacogenomics clinic. <b>Materials & methods:</b> A 16-item anonymous survey was sent to healthcare professionals practicing at Tampa General Hospital and the University of South Florida Health. <b>Results:</b> Survey participants consisted of nine advanced practice providers, 41 pharmacists and 64 physicians. Majority of survey participants did not feel confident in their ability to interpret and apply pharmacogenomic results. In the past 12 months, 27% of physicians reported ordering a pharmacogenomic test. The greatest reported barrier to integrating pharmacogenomics was the absence of established guidelines or protocols. <b>Conclusion:</b> Most clinicians believed pharmacogenomics would be useful in their clinical practice but do not feel prepared to interpret pharmacogenomic results.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"19 1","pages":"15-23"},"PeriodicalIF":2.3,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39794456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Biomarker-driven immunotherapy for precision medicine in prostate cancer. 生物标志物驱动免疫疗法在前列腺癌精准医学中的应用。
IF 2.3 4区 医学
Personalized medicine Pub Date : 2022-01-01 Epub Date: 2021-12-07 DOI: 10.2217/pme-2021-0079
Arianna Ottini, Pierangela Sepe, Teresa Beninato, Mélanie Claps, Valentina Guadalupi, Elena Verzoni, Patrizia Giannatempo, Giulia Baciarello, Filippo de Braud, Giuseppe Procopio
{"title":"Biomarker-driven immunotherapy for precision medicine in prostate cancer.","authors":"Arianna Ottini,&nbsp;Pierangela Sepe,&nbsp;Teresa Beninato,&nbsp;Mélanie Claps,&nbsp;Valentina Guadalupi,&nbsp;Elena Verzoni,&nbsp;Patrizia Giannatempo,&nbsp;Giulia Baciarello,&nbsp;Filippo de Braud,&nbsp;Giuseppe Procopio","doi":"10.2217/pme-2021-0079","DOIUrl":"https://doi.org/10.2217/pme-2021-0079","url":null,"abstract":"<p><p>Although immunotherapy has recently revolutionized standard of care in different cancer types, prostate cancer has generally failed to show dramatic responses to immune checkpoint inhibitors. As in other tumors, the goal in prostate cancer is now to target treatments more precisely on patient's individual characteristics through precision medicine. Defects in mismatch repair, mutations in the exonuclease domain of the DNA polymerase epsilon (<i>POLE</i>), high tumor mutational burden and the presence of biallelic loss of <i>CDK12</i> among others, are predictive biomarkers of response to immunotherapy. In the present review, we summarize the evolving landscape of immunotherapy in prostate cancer, including precision approaches and strategies to define classes of responsive patients and scale up resistance to immune checkpoint inhibitors.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"19 1","pages":"51-66"},"PeriodicalIF":2.3,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39812110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Welcome to the 19th volume of Personalized Medicine. 欢迎来到《个性化医疗》第19卷。
IF 2.3 4区 医学
Personalized medicine Pub Date : 2022-01-01 DOI: 10.2217/pme-2021-0138
Ryan Gilroy
{"title":"Welcome to the 19th volume of <i>Personalized Medicine</i>.","authors":"Ryan Gilroy","doi":"10.2217/pme-2021-0138","DOIUrl":"https://doi.org/10.2217/pme-2021-0138","url":null,"abstract":"","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"19 1","pages":"1-4"},"PeriodicalIF":2.3,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39834964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信